Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study d...
B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $42 price target.
Company is actively seeking partnership opportunities to support future development of BBP-631 or next-generation gene therapie...
BBP-631 has been well tolerated with only mild to moderate treatment-emergent adverse events (TEAEs) and no treatment-related S...
BBP-812 is an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canav...
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price ...
Piper Sandler analyst Biren Amin initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Overweight rating and announces...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...
